A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456

NCT04008849 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2021-03-15

No results posted yet for this study

Summary

A follow-up study to evaluate the safety and clinical outcomes of patients with inherited metabolic disorders (IMD) who have undergone hematopoietic stem cell transplantation (HSCT) with MGTA-456

Conditions

  • Inherited Metabolic Disorders (IMD)

Interventions

OTHER

Safety and efficacy assessments

Long term safety and clinical outcomes

Sponsors & Collaborators

  • Magenta Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Paul J Orchard, MD · University of Minnesota

Eligibility

Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-21
Primary Completion
2020-10-08
Completion
2020-10-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04008849 on ClinicalTrials.gov